GlycoSyn IRL Homepage
Cylinders.

News

 

Royal Society of New Zealand honours GM of GlycoSyn

December 2006

GlycoSyn's General Manager, Dr Richard Furneaux, has been awarded the Hector Medal from the Royal Society of New Zealand.

 

Industrial Research and Institute of Molecular and Cell Biology to collaborate on stem cell research

September 2006

The work will ultimately target new therapeutics for bone healing and is seen as the beginnings of a broader research and development partnership with Singapore.

 

GlycoSyn works on Parkinson’s Drug

August 2006

GlycoSyn has nearly completed the manufacture of the key ingredient for a new drug designed to slow the progression of Parkinson’s Disease.

 

A winning year for IRL and Australasia’s biotechnology industry

July 2006

Industrial Research Limited’s (IRL) Carbohydrate Chemistry platform has delivered the Australasian Biotech industry’s biggest year on record - since the industry was founded in Australia and New Zealand in the mid 1980’s.

 

Industrial Research Limited lands significant pharmaceutical production deal

July 2006

The active ingredient for a new drug designed to prevent genital herpes and HIV-AIDS will be manufactured in New Zealand with the signing of a major contract.

 

Starpharma and Industrial Research Ltd Establish Joint Venture to
Commercialise Glycodendrimers as Pharmaceuticals - Joint Venture Supported by $NZ945,000 Grant

Melbourne, Australia, 3 March 2005

Starpharma Holdings Limited (ASX: SPL, USOTC:SPHRY) of Melbourne, Australia and Industrial Research Limited, New Zealand, today announced that they have entered into a joint venture to accelerate the development of carbohydrate functionalised dendrimers (glycodendrimers) for use in therapeutics, antigen presentation and as biologically active compounds.

 

Forerunner of New Pharmaceutical Industry in New Zealand

March 2003

New Zealand's potential as a high-value manufacturer of next generation drugs that target cancer and other diseases was signalled with the opening of a $7 million facility in Lower Hutt today (26 March 2003)

 

New era for New Zealand organic chemistry synthesis capability

November 2002

New Zealand's ability to take newly discovered pharmaceutical candidates all the way from the laboratory to human clinical trials will receive a boost with the opening in March 2003 of a new $6 million glycotherapeutics synthesis development and production facility.